Lexston Life Sciences Corp. (TSE:LEXT)
CNQX:LEXT
Canadian Market

Lexston Life Sciences Corp. (LEXT) Income Statement

3 Followers

Lexston Life Sciences Corp. Income Statement

Last quarter (Q2 2024), Lexston Life Sciences Corp.'s total revenue was C$―, a decrease of ― from the same quarter last year. In Q2, Lexston Life Sciences Corp.'s net income was C$-138.18K. See Lexston Life Sciences Corp.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
May 23May 22May 21
Total Revenue
--C$ 361.01KC$ 149.11K
Cost of Revenue
--C$ 119.52KC$ 89.01K
Gross Profit
--C$ 241.49KC$ 60.10K
Operating Expense
C$ 644.87KC$ 1.09MC$ 2.12MC$ 551.19K
Operating Income
C$ -644.87KC$ -1.09MC$ -1.87MC$ -491.09K
Net Non Operating Interest Income Expense
----
Other Income Expense
C$ -5.17KC$ 15.75KC$ -92.85KC$ -385.04K
Pretax Income
C$ -639.70KC$ -1.11MC$ -2.07MC$ -876.13K
Tax Provision
----
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
C$ -639.70KC$ -1.11MC$ -2.07MC$ -876.13K
Basic EPS
C$ -0.01C$ -0.04C$ -0.21C$ -0.09
Diluted EPS
C$ -0.01C$ -0.04C$ -0.21C$ -0.09
Basic Average Shares
C$ 121.18MC$ 28.58MC$ 11.16MC$ 10.15M
Diluted Average Shares
C$ 121.18MC$ 28.58MC$ 11.16MC$ 10.15M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
---C$ 16.10K
Total Expenses
C$ 644.87KC$ 1.09MC$ 2.24MC$ 640.20K
Net Income From Continuing And Discontinued Operation
C$ -639.70KC$ -1.11MC$ -2.07MC$ -876.13K
Normalized Income
C$ -485.18KC$ -809.00KC$ -1.23MC$ -491.09K
Interest Expense
----
EBIT
C$ -639.70KC$ -1.11MC$ -2.07MC$ -491.09K
EBITDA
C$ -612.90KC$ -1.08MC$ -2.04MC$ -479.82K
Currency in CAD

Lexston Life Sciences Corp. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis